Invivyd’s (IVVD) “Buy” Rating Reiterated at D. Boral Capital

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating reiterated by equities researchers at D. Boral Capital in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $9.00 target price on the stock.

Several other equities analysts have also commented on IVVD. Morgan Stanley dropped their price target on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research report on Wednesday, November 20th. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Invivyd in a research report on Monday, February 24th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Invivyd currently has an average rating of “Buy” and a consensus price target of $7.89.

Invivyd Price Performance

IVVD stock traded up $0.02 on Thursday, hitting $0.74. 3,868,660 shares of the company were exchanged, compared to its average volume of 17,470,254. Invivyd has a twelve month low of $0.35 and a twelve month high of $4.74. The business’s fifty day moving average is $0.97 and its two-hundred day moving average is $0.87. The stock has a market capitalization of $88.52 million, a price-to-earnings ratio of -0.38 and a beta of 0.09.

Invivyd (NASDAQ:IVVD) last issued its quarterly earnings results on Thursday, March 20th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.10. Equities research analysts expect that Invivyd will post -1.64 earnings per share for the current year.

Insider Transactions at Invivyd

In other news, Director Terrance Mcguire sold 119,805 shares of the company’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $0.42, for a total value of $50,318.10. Following the completion of the transaction, the director now directly owns 3,568,274 shares in the company, valued at approximately $1,498,675.08. This represents a 3.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 365,943 shares of company stock valued at $171,220 over the last 90 days. Corporate insiders own 17.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in IVVD. State Street Corp boosted its stake in shares of Invivyd by 3.7% in the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock valued at $1,039,000 after purchasing an additional 35,904 shares during the period. Barclays PLC boosted its stake in Invivyd by 179.6% during the 3rd quarter. Barclays PLC now owns 117,973 shares of the company’s stock valued at $120,000 after acquiring an additional 75,780 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Invivyd by 644.1% during the 4th quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company’s stock valued at $114,000 after acquiring an additional 222,375 shares during the last quarter. Renaissance Technologies LLC bought a new position in Invivyd during the 4th quarter valued at $74,000. Finally, Jane Street Group LLC boosted its stake in Invivyd by 290.5% during the 4th quarter. Jane Street Group LLC now owns 117,432 shares of the company’s stock valued at $52,000 after acquiring an additional 87,358 shares during the last quarter. 70.36% of the stock is currently owned by hedge funds and other institutional investors.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.